Berlin: Dr. Falk Pharma GmbH, a pharmaceutical company with a focus on digestive and metabolic medicine, and Renexxion Ireland Limited, a clinical-stage biopharmaceutical company, announced favorable results from the global Phase 2b MOVE-IT trial. This trial evaluated the efficacy, safety, and tolerability of naronapride for adults suffering from gastroparesis.

According to BERNAMA News Agency, the double-blind, multicenter study spanned 12 weeks and included 328 adults exhibiting moderate-to-severe symptoms of idiopathic or diabetic gastroparesis. These participants also showed objective evidence of delayed gastric emptying. The trial assigned patients to receive either 10 mg, 20 mg, or 40 mg doses of naronapride, or a placebo, administered orally three times daily over the course of 12 weeks.